Cargando…

Clinical improvement of DM1 patients reflected by reversal of disease-induced gene expression in blood

BACKGROUND: Myotonic dystrophy type 1 (DM1) is an incurable multisystem disease caused by a CTG-repeat expansion in the DM1 protein kinase (DMPK) gene. The OPTIMISTIC clinical trial demonstrated positive and heterogenous effects of cognitive behavioral therapy (CBT) on the capacity for activity and...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Cruchten, Remco T. P., van As, Daniël, Glennon, Jeffrey C., van Engelen, Baziel G. M., ‘t Hoen, Peter A. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646470/ https://www.ncbi.nlm.nih.gov/pubmed/36352383 http://dx.doi.org/10.1186/s12916-022-02591-y

Ejemplares similares

Blood Transcriptome Profiling Links Immunity to Disease Severity in Myotonic Dystrophy Type 1 (DM1)
por: Nieuwenhuis, Sylvia, et al.
Publicado: (2022)

Insulin Signaling as a Key Moderator in Myotonic Dystrophy Type 1
por: Nieuwenhuis, Sylvia, et al.
Publicado: (2019)

Cognitive behaviour therapy plus aerobic exercise training to increase activity in patients with myotonic dystrophy type 1 (DM1) compared to usual care (OPTIMISTIC): study protocol for randomised controlled trial
por: van Engelen, Baziel
Publicado: (2015)

Clinical Outcome Evaluations and CBT Response Prediction in Myotonic Dystrophy
por: van As, Daniël, et al.
Publicado: (2021)

(CTG)n repeat-mediated dysregulation of MBNL1 and MBNL2 expression during myogenesis in DM1 occurs already at the myoblast stage
por: André, Laurène M., et al.
Publicado: (2019)

A comprehensive atlas of fetal splicing patterns in the brain of adult myotonic dystrophy type 1 patients
por: Degener, Max J F, et al.
Publicado: (2022)

Hereditable variants of classical protein tyrosine phosphatase genes: Will they prove innocent or guilty?
por: Hendriks, Wiljan J. A. J., et al.
Publicado: (2023)

The FSHD muscle–blood biomarker: a circulating transcriptomic biomarker for clinical severity in facioscapulohumeral muscular dystrophy
por: Banerji, Christopher R S, et al.
Publicado: (2023)

Longitudinal Assessment of Strength, Functional Capacity, Oropharyngeal Function, and Quality of Life in Oculopharyngeal Muscular Dystrophy
por: Kroon, Rosemarie H.M.J.M., et al.
Publicado: (2021)

Block or degrade? Balancing on- and off-target effects of antisense strategies against transcripts with expanded triplet repeats in DM1
por: El Boujnouni, Najoua, et al.
Publicado: (2023)

Reversal and Remission of T2DM – An Update for Practitioners
por: Shibib, Lina, et al.
Publicado: (2022)

Expanded CUG repeats in DMPK transcripts adopt diverse hairpin conformations without influencing the structure of the flanking sequences
por: van Cruchten, Remco T.P., et al.
Publicado: (2019)

Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy
por: Greco, Anna, et al.
Publicado: (2020)

Common disease signatures from gene expression analysis in Huntington’s disease human blood and brain
por: Mina, Eleni, et al.
Publicado: (2016)

Systemic cell therapy for muscular dystrophies: The ultimate transplantable muscle progenitor cell and current challenges for clinical efficacy
por: Ausems, C. Rosanne M., et al.
Publicado: (2020)

Reproducibility and robustness of motor cortical stimulation to assess muscle relaxation kinetics
por: Molenaar, Joery P., et al.
Publicado: (2022)

The Virtual-Environment-Foraging Task enables rapid training and single-trial metrics of rule acquisition and reversal in head-fixed mice
por: Havenith, Martha N., et al.
Publicado: (2019)

A decline in PABPN1 induces progressive muscle weakness in Oculopharyngeal muscle dystrophy and in muscle aging
por: Anvar, Seyed Yahya, et al.
Publicado: (2013)

Identifying a gene expression signature of cluster headache in blood
por: Eising, Else, et al.
Publicado: (2017)

Effects of shared medical appointments on quality of life and cost-effectiveness for patients with a chronic neuromuscular disease. Study protocol of a randomized controlled trial
por: Seesing, Femke M, et al.
Publicado: (2011)

Upscaling Reverse Electrodialysis
por: Moreno, Jordi, et al.
Publicado: (2018)

Inspiratory Muscle Training in Nemaline Myopathy
por: van Kleef, Esmee S.B., et al.
Publicado: (2023)

Five‐year follow‐up study on quantitative muscle magnetic resonance imaging in facioscapulohumeral muscular dystrophy: The link to clinical outcome
por: Vincenten, Sanne C.C., et al.
Publicado: (2023)

Semi‐automated Rasch analysis using in‐plus‐out‐of‐questionnaire log likelihood
por: Wijayanto, Feri, et al.
Publicado: (2020)

Quantitative muscle MRI and ultrasound for facioscapulohumeral muscular dystrophy: complementary imaging biomarkers
por: Mul, Karlien, et al.
Publicado: (2018)

NA-CONTROL: a study protocol for a randomised controlled trial to compare specific outpatient rehabilitation that targets cerebral mechanisms through relearning motor control and uses self-management strategies to improve functional capability of the upper extremity, to usual care in patients with neuralgic amyotrophy
por: Lustenhouwer, Renee, et al.
Publicado: (2019)

Care for capabilities: Implementing the capability approach in rehabilitation of patients with neuromuscular diseases. Study protocol of the controlled before-after ReCap-NMD study
por: Bloemen, Bart, et al.
Publicado: (2021)

Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology
por: Bhansing, Kavish J, et al.
Publicado: (2014)

Deregulation of the ubiquitin-proteasome system is the predominant molecular pathology in OPMD animal models and patients
por: Anvar, Seyed Yahya, et al.
Publicado: (2011)

Effectiveness and cost-effectiveness of a self-management group program to improve social participation in patients with neuromuscular disease and chronic fatigue: protocol of the Energetic study
por: Veenhuizen, Yvonne, et al.
Publicado: (2015)

Evaluation of blood gene expression levels in facioscapulohumeral muscular dystrophy patients
por: Signorelli, M., et al.
Publicado: (2020)

Behavioural Impairment and Frontotemporal Dementia in Oculopharyngeal Muscular Dystrophy
por: Tankink, Maurits, et al.
Publicado: (2022)

ASO Author Reflections: The Changing Role of Gene Expression Profiling in ER+/HER2− Breast Cancer
por: van Steenhoven, Julia E. C., et al.
Publicado: (2019)

N-of-1 Trials: Evidence-Based Clinical Care or Medical Research that Requires IRB Approval? A Practical Flowchart Based on an Ethical Framework
por: Stunnenberg, Bas C., et al.
Publicado: (2020)

Indications for Tube Feeding in Adults with Muscular Disorders: A Scoping Review
por: Middelink, Marloes, et al.
Publicado: (2023)

Effect of aerobic exercise training and cognitive behavioural therapy on reduction of chronic fatigue in patients with facioscapulohumeral dystrophy: protocol of the FACTS-2-FSHD trial
por: Voet, Nicoline BM, et al.
Publicado: (2010)

High disease impact of myotonic dystrophy type 2 on physical and mental functioning
por: Tieleman, Alide A., et al.
Publicado: (2011)

Nature and frequency of respiratory involvement in chronic progressive external ophthalmoplegia
por: Smits, Bart W., et al.
Publicado: (2011)

Cortical Iron Reflects Severity of Alzheimer’s Disease
por: van Duijn, Sara, et al.
Publicado: (2017)

The socioeconomic burden of facioscapulohumeral muscular dystrophy
por: Blokhuis, Anna M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_715n3ip87gc1b25d2jie1padpo